Privia Health Group (NASDAQ:PRVA) Price Target Raised to $23.00

Privia Health Group (NASDAQ:PRVA) had its price objective lifted by Barclays from $21.00 to $23.00 in a report issued on Thursday morning,Benzinga reports. The firm currently has an equal weight rating on the stock.

A number of other equities research analysts have also issued reports on PRVA. JMP Securities set a $29.00 price target on Privia Health Group in a research note on Friday, February 28th. Stephens reissued an “overweight” rating and issued a $26.00 price objective on shares of Privia Health Group in a research note on Thursday, January 2nd. Canaccord Genuity Group boosted their target price on Privia Health Group from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Piper Sandler raised their price objective on shares of Privia Health Group from $25.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Finally, Truist Financial boosted their target price on shares of Privia Health Group from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $26.87.

Privia Health Group Trading Up 1.9 %

Shares of NASDAQ:PRVA opened at $24.10 on Thursday. The stock has a 50 day moving average of $23.76 and a 200 day moving average of $21.49. The company has a market cap of $2.92 billion, a PE ratio of 241.02, a price-to-earnings-growth ratio of 3.47 and a beta of 0.88. Privia Health Group has a 12-month low of $15.92 and a 12-month high of $26.04.

Insider Transactions at Privia Health Group

In related news, CFO David Mountcastle sold 5,630 shares of Privia Health Group stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total transaction of $125,999.40. Following the transaction, the chief financial officer now owns 179,676 shares in the company, valued at approximately $4,021,148.88. This trade represents a 3.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 14.20% of the company’s stock.

Institutional Trading of Privia Health Group

Hedge funds and other institutional investors have recently modified their holdings of the business. Rhumbline Advisers raised its holdings in shares of Privia Health Group by 1.3% in the 4th quarter. Rhumbline Advisers now owns 287,200 shares of the company’s stock valued at $5,615,000 after buying an additional 3,658 shares during the period. Nordea Investment Management AB increased its stake in Privia Health Group by 33.1% during the fourth quarter. Nordea Investment Management AB now owns 349,773 shares of the company’s stock worth $6,953,000 after purchasing an additional 86,910 shares during the period. Franklin Resources Inc. lifted its position in shares of Privia Health Group by 2.2% during the third quarter. Franklin Resources Inc. now owns 1,300,240 shares of the company’s stock worth $23,092,000 after purchasing an additional 28,480 shares in the last quarter. Barclays PLC lifted its position in shares of Privia Health Group by 240.3% during the third quarter. Barclays PLC now owns 224,018 shares of the company’s stock worth $4,079,000 after purchasing an additional 158,188 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Privia Health Group by 8.4% in the third quarter. JPMorgan Chase & Co. now owns 188,384 shares of the company’s stock valued at $3,430,000 after purchasing an additional 14,641 shares in the last quarter. 94.48% of the stock is owned by institutional investors and hedge funds.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.